Synlogic Presents Additional Preclinical Data on Therapeutic Candidates SYNB1934 for Phenylketonuria (PKU) and SYNB8802 for Enteric Hyperoxaluria at Synthetic Biology: Engineering, Evolution & Design (SEED) Conference
The two posters will be available throughout the duration of the conference:
- Synthetic Biology Approaches for the Optimization and Improvement of a Live Bacterial Therapeutic for the Treatment of Phenylketonuria (PKU)
- Development of a Synthetic Biotic, SYNB8802, for the treatment of Enteric Hyperoxaluria
SYNB1934 is an evolved strain of SYNB1618, developed to provide a potentially greater degree of phenylalanine (Phe)-lowering relative to SYNB1618. Data from preclinical in vivo and in vitro studies demonstrated a greater than 2-fold improvement in the ability of SYNB1934 to metabolize Phe compared to SYNB1618.
"The progression of SYNB1934 highlights
SYNB8802 is an oral investigational drug for the treatment of Enteric Hyperoxaluria. The data presented characterizes in vitro and in vivo activity of SYNB8802 and, using proprietary gut simulation techniques, provides evidence of strain activity throughout the GI tract.
About Enteric Hyperoxaluria
Enteric Hyperoxaluria is an acquired metabolic disorder caused by increased absorption of dietary oxalate, which is present in many healthy foods, making it almost impossible to control with diet alone. Enteric Hyperoxaluria often occurs as a result of a primary insult to the bowel, such as inflammatory bowel disease, short bowel syndrome, or as a result of surgical procedures such as Roux-en-Y bariatric weight-loss surgery. Enteric Hyperoxaluria results in dangerously high levels of urinary oxalate, which causes progressive kidney damage, kidney stone formation, and nephrocalcinosis. There are no approved treatment options.
Phenylketonuria (PKU) is an inherited metabolic disease that manifests at birth and is marked by an inability to break down phenylalanine (Phe), an amino acid that is commonly found in many foods. Left untreated, high levels of Phe become toxic and can lead to serious neurological and neuropsychological problems affecting the way a person thinks, feels, and acts. Due to the seriousness of these symptoms, infants are screened at birth in many countries to ensure early diagnosis and treatment to avoid intellectual disability and other complications.
Synlogic™ is bringing the transformative potential of synthetic biology to medicine. With a premiere synthetic biology platform that leverages a reproducible, modular approach to microbial engineering,
This press release contains "forward-looking statements" that involve substantial risks and uncertainties for purposes of the safe harbor provided by the Private Securities Litigation Reform Act of 1995. All statements, other than statements of historical facts, included in this press release regarding strategy, future operations, clinical development plans, future financial position, future revenue, projected expenses, prospects, plans and objectives of management are forward-looking statements. In addition, when or if used in this press release, the words "may," "could," "should," "anticipate," "believe," "estimate," "expect," "intend," "plan," "predict" and similar expressions and their variants, as they relate to
View original content:http://www.prnewswire.com/news-releases/synlogic-presents-additional-preclinical-data-on-therapeutic-candidates-synb1934-for-phenylketonuria-pku-and-synb8802-for-enteric-hyperoxaluria-at-synthetic-biology-engineering-evolution--design-seed-conference-301312771.html
Media Contact: Christen Baglaneas, Synlogic, Inc., Phone: 617-401-9152, Email: firstname.lastname@example.org; Investor Contact: Daniel Rosan, Synlogic, Inc., Phone: 617-401-9152, Email: email@example.com